Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab and SBRT in Cervical Cancer
NCT03614949Phase 2Active, not recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Jan 2019
- Primary completion
- Oct 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab in Cervical Cancer (CC), sponsored by Moffitt Cancer Center. Started Jan 2019; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT03614949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03614949.